Drug Trial Radar · NCT07142291
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Mar 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- PhenoNet, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID)Drug
17.1 mg, BID, oral inhalation
Cromolyn Sodium (17.1 mg BID)Drug
34.2 mg, BID, oral inhalation via dry powder inhaler
PlaceboDrug
Placebo comparator matched to active treatment.
Riluzole (100 mg)Drug
50 mg, oral tablet, BID, standard of care treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change in ALSFRS-R total score from baseline to Week 24Time frame: Baseline to Week 24
- Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline to Week 24
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Honor Health Neurology - Bob Bove Neuroscience Institute
Scottsdale, Arizona · Recruiting
University of California San Diego
La Jolla, California · Recruiting
Sutter Health - California Pacific Medical Center Research Institute
San Francisco, California · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Lange Neurology
New York, New York · Recruiting
NEUROHK s.r.o.
Hradec Králové, Czechia · Recruiting
Fakultni Nemocnice Hradec Kralove
Hradec Králové, Czechia · Recruiting
Thomayer University Hospital - Fakultni Thomayerova nemocnice
Prague, Czechia · Recruiting
Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie
Berlin, Germany · Recruiting
DIAKOVERE Henriettenstift - Klinik für Neurologie und Klinische Neurophysiologie
Hanover, Germany · Recruiting
Universitaetsklinikum Schleswig-Holstein
Lübeck, Germany · Recruiting
Michalski i Partnerzy Lekarze Spółka Partnerska
Krakow, Poland · Recruiting
SP ZOZ Szpital Uniwersytecki w Krakowie
Krakow, Poland · Recruiting
Centrum Medyczne NeuroProtect (NeuroProtect Medical Center)
Warsaw, Poland · Recruiting
City Clinic Research
Warsaw, Poland · Recruiting
University Clinical Center of Serbia
Belgrade, Serbia · Recruiting
Hospital General Universitario Dr. Balmis de Alicante
Alicante, Spain · Recruiting
Barcelona Sea Hospital (Hospital Del Mar De Barcelona)
Barcelona, Spain · Recruiting
Hospital Universitario Vall D Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Ramon Y Cajal
Madrid, Spain · Recruiting
Hospital Regional Universitario De Malaga
Málaga, Spain · Recruiting
Hospital Universitario Virgen Del Rocio
Seville, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.